Keywords
quality of life
psychological stress
pain
loneliness
anxiety.
Abstract
Introduction: Fibromyalgia (FM) is a complex disorder with significant impact on public health. Few studies have explored suffering in FM, since its approach focuses on pain management. Objective: To estimate the prevalence of suffering in patients with FM and its association with impact on quality of life, emotional distress, loneliness, vital stress and clinical and sociodemographic factors in a private healthcare institution in Medellín (Colombia). Method: A cross-sectional study was conducted in an institution specialized in chronic pain management. The degree of suffering (PRISM), level of pain (EVA), impact of FM (FIQR), loneliness (UCLA), anxiety and depression (HADS), stressful life events (CSV) and sociodemographic and clinical characteristics were evaluated. An explanatory model was proposed using logistic regression. Results: 55.5 % IC95 (50,0-61,1) presented intense suffering. An explanatory model was obtained, where impact, depression and analgesic intake were the most relevant factors in intense suffering. Discussion: Patients with FM manifest an important suffering that should be attended by health personnel. Although pain is a relevant element, there are other factors to which attention should be paid, such as the impact of the disease on the person and the associated depression.References
1. Cassell EJ, Rich BA. Intractable end-of-life suffering and the ethics of palliative sedation. Pain Med Malden Mass. 2010;11(3):435-8.
2. del Giglio A. Suffering-based medicine: practicing scientific medicine with a humanistic approach. Med Health Care Philos. 2020;23(2):215-9.
3. Krikorian A, Limonero JT, Corey MT. Suffering Assessment: A Review of Available Instruments for Use in Palliative Care. J Palliat Med. 2013;16(2):130-42.
4. Krikorian A, Limonero JT, Maté J. Suffering and distress at the end-of-life: Suffering and distress at the end-of-life. Psychooncology. 2012;21(8):799-808.
5. Paschali M, Lazaridou A, Vilsmark ES, Lee J, Berry M, Grahl A, et al. The “self” in pain: high levels of schema-enmeshment worsen fibromyalgia impact. BMC Musculoskelet Disord. 2021;22(1):871.
6. Londoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Rev Colomb Reumatol. 2018;25(4):245-56.
7. Compañ V, Feixas G, Varlotta-Domínguez N, Torres-Viñals M, Aguilar-Alonso Á, Dada G, et al. Cognitive Factors in Fibromyalgia: The Role of Self-Concept and Identity Related Conflicts. J Constr Psychol. 2011;24(1):56-77.
8. Cardona-Arias JA, Hernández-Petro AM, León-Mira V. Validez, fiabilidad y consistencia interna de tres instrumentos de medición de calidad de vida relacionada con la salud en personas con fibromialgia, Colombia. Rev Colomb Reumatol. 2014;21(2):57-64.
9. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire. J Rheumatol. 2009;36(6):1304-11.
10. Velarde-Mayol C, Fragua-Gil S, García-de-Cecilia JM. Validación de la escala de soledad de UCLA y perfil social en la población anciana que vive sola. Med Fam-SEMERGEN. 2016;42(3):177-83.
11. Russell D, Peplau LA, Cutrona CE. The revised UCLA Loneliness Scale: Concurrent and discriminant validity evidence. J Pers Soc Psychol. 1980;39(3):472-80.
12. Russell DW. UCLA Loneliness Scale (Version 3): Reliability, Validity, and Factor Structure. J Pers Assess. 1996;66(1):20-40.
13. Cabrera V, Martín-Aragón M, Terol M del C, Núñez R, Pastor M de los Á. La Escala de Ansiedad y Depresión Hospitalaria (HAD) en fibromialgia: Análisis de sensibilidad y especificidad. Ter Psicológica. 2015;33(3):181-93.
14. Rico J, Forero MR, Molina M. Adaptación y validación de la escala hospitalaria de ansiedad y depresión (HAD) en una muestra de pacientes con cáncer del Instituto Nacional de Cancerología de Colombia. Av En Medición. 2005;3(1):73-86.
15. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-70.
16. Sandín B, Chorot P. Cuestionario de Sucesos Vitales (CSV): Estructura factorial, características psicométricas y datos normativos. Rev Psicopatología Psicol Clínica. 2017;22(2):95.
17. Grant RL. Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ. 2014;348(jan24 1):f7450-f7450.
18. Cabrera V, Martín-Aragón M, Terol M del C, Núñez R, Pastor M de los Á. La Escala de Ansiedad y Depresión Hospitalaria (HAD) en fibromialgia: Análisis de sensibilidad y especificidad. Ter Psicológica. 2015;33(3):181-93.
19. Offenbaecher M, Kohls N, Ewert T, Sigl C, Hieblinger R, Toussaint LL, et al. Pain is not the major determinant of quality of life in fibromyalgia: results from a retrospective “real world” data analysis of fibromyalgia patients. Rheumatol Int. 2021;41(11):1995-2006.
20. Galvez-Sánchez CM, Duschek S, Reyes del Paso GA. Psychological impact of fibromyalgia: current perspectives. Psychol Res Behav Manag. 2019;12:117-27.
21. Sener U, Ucok K, Ulasli AM, Genc A, Karabacak H, Coban NF, et al. Evaluation of health-related physical fitness parameters and association analysis with depression, anxiety, and quality of life in patients with fibromyalgia. Int J Rheum Dis. 2016;19(8):763-72.
22. Fibromyalgia position paper [Internet]. Clin Exp Rheumatol. [citado 13 de diciembre de 2022]. Disponible en: https://www.clinexprheumatol.org/abstract.asp?a=17133
23. Yager J. Addressing Suffering in Patients With Psychiatric Disorders. J Nerv Ment Dis. 2021;209(9):615-21.
24. Pérez Martín Y, Pérez Muñoz M, García Ares D, Fuentes Gallardo I, Rodríguez Costa I. El cuerpo duele, y el dolor social… ¿Duele también? Aten Primaria. 2020;52(4):267-72.
25. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-28.
26. Chen X, Zou K, Abdullah N, Whiteside N, Sarmanova A, Doherty M, et al. The placebo effect and its determinants in fibromyalgia: meta-analysis of randomised controlled trials. Clin Rheumatol. 2017;36(7):1623-30
27. Fibromialgia: prevalencia, perfiles epidemiológicos y costes económicos. Med Clin (Barc). 2017;149(10):441-8.
28. Fishbain DA, Lewis JE, Gao J. The Pain—Suffering Association, A Review. Pain Med. 2015;16(6):1057-72.